文献速递治疗药物监测与药物基因组学药物相互作用

液体活检或治疗药物监测用于CYP活性谱确定

Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination.
PubMed 文献 · Clin Pharmacol Ther · 2022-07-26

研究在96份供体匹配肝样本中验证肝脏CYP基因mRNA表达与酶特异性药物代谢速率的相关性,发现平均Pearson相关系数为0.28,最高为CYP2D6和CYP3A4(0.33-0.34),相关性太弱不足以预测,提示液体活检尚不能替代TDM。

要点

  • 肝CYP mRNA表达与药物代谢速率相关性弱,平均r=0.28。
  • CYP2D6和CYP3A4相关性最高(0.33-0.34),CYP1A2和CYP2B6最弱(0.18-0.21)。
  • 液体活检预测CYP蛋白表达可能有价值,但目前不能替代TDM。

核心结论

  • 液体活检虽可能预测肝脏CYP蛋白表达,但当前不足以替代治疗药物监测。

研究设计与样本

  • 研究分析了96份供体匹配肝样本中8种CYP基因mRNA表达与肝微粒体CYP依赖药物代谢速率的相关性。

主要发现

  • CYP基因mRNA表达与酶特异性药物代谢速率的平均Pearson相关系数为0.28。
  • CYP2D6和CYP3A4相关性最高(0.33-0.34),CYP1A2和CYP2B6最弱(0.18-0.21)。
  • 所有相关性均太弱,不足以证明预测关系。

关键数值与推荐

  • 平均Pearson相关系数0.28,CYP2D6和CYP3A4为0.33-0.34,CYP1A2和CYP2B6为0.18-0.21。

临床怎么用

  • 临床不应以液体活检cfRNA替代TDM进行CYP活性评估和剂量调整。

局限性

  • 相关性弱可能源于不同调控和翻译后事件控制酶活性速率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During pharmacotherapy, knowledge about the actual drug and metabolite concentrations in plasma is often critical. Individual dose adjustments can be performed based on pre-emptive genotyping of certain absorption, distribution, metabolism, and excretion (ADME) genes but also using therapeutic drug monitoring (TDM). Analyses of liquid biopsies for tumor-derived components are well-established and have been found to be a good complement to biopsy examinations. Recently, liquid biopsy-based quantification of cell-free RNA (cfRNA) in plasma exosomes was proposed as a proxy measurement for the expression of different hepatic ADME genes and for the rate of drug metabolism, constituting an alternative to TDM. In this study, we validated these findings by examining the correlation between mRNA expression of eight different CYP genes in liver and the corresponding rate of enzyme-specific drug metabolism in 96 donor-matched liver samples. Analyses of CYP-dependent drug metabolism in liver microsomes in comparison to the level of mRNA expression for the different CYP genes revealed a mean Pearson correlation coefficient of 0.28. The highest correlations (0.33-0.34) were obtained for CYP2D6 and CYP3A4 and the weakest correlations were observed for CYP1A2 and CYP2B6 (0.18-0.21). In all cases, the correlations obtained were too weak to demonstrate a predictive relationship, likely due to different regulatory and post-translational events controlling the rate of enzyme activity. Our results reinforce the notion that, whilst liquid biopsy-based approaches might have utility for prediction of hepatic CYP protein expression, they are not currently an important substitute for TDM.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pridgeon CS, Johansson I, Ingelman-Sundberg M, et al. Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination. Clin Pharmacol Ther. 2022. PMID: 35766115. doi:10.1002/cpt.2695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。